Abbisko Therapeutics’ Pimicotinib (ABSK021) Receives Breakthrough Therapy Designation from FDA for Treatment of Tenosynovial Giant Cell Tumor
Abbisko Therapeutics today announced that its CSF-1R inhibitor Pimicotinib（ABSK021）has been granted the breakthrough therapy designation from FDA for the treatment of tenosynovial giant cell tumor (TG ...